More than enough testing of CBD has occurred to satisfy those who read up on it, but if it's not FDA approved from accredited labs then it's not considered viable evidence. We all know why it has taken so long. The FDA has been working in the best interests of big pharmaceutical companies. That's changing, and the move to schedule 3 will prove to be a major factor in that change.
(5)
(0)
Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links